Clinical trials sponsored by Hunan Province Tumor Hospital

Phase breakdown

Conditions studied

Recruiting trials led by Hunan Province Tumor Hospital

• A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
  NCT06183762 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer
  NCT05991193 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC
  NCT04324125 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
  NCT05059951 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
  NCT05055908 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases
  NCT06440954 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
  NCT05284539 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
  NCT05379803 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy
  NCT05584267 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
  NCT04951947 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
  NCT04324151 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
  NCT05266846 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
  NCT06355609 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC
  NCT06348927 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
  NCT04324164 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
  NCT06109558 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.
  NCT04777084 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Common questions

How many trials is Hunan Province Tumor Hospital recruiting for?

Hunan Province Tumor Hospital is the lead sponsor of 17 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.